➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Boehringer Ingelheim
Johnson and Johnson
Merck
McKinsey

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,707,272

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,707,272
Title:Method for the treatment of acne by administering IL-1.beta. antibody
Abstract: The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1.beta., IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1.beta., IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1.beta., I L-1.beta. receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.
Inventor(s): Jankovic; Dragana (Basel, CH), Kistowska; Magdalena (Dietikon, CH), Contassot; Emmanuel (Buschwiller, FR), French; Lars E. (Schweiz, CH), Gehrke; Samuel (Rapperswil, CH)
Assignee: UNIVERSITAT ZURICH (Zurich, CH)
Application Number:14/232,272
Patent Claims:see list of patent claims

Details for Patent 9,707,272

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis Pharms ILARIS canakinumab INJECTABLE; SUBCUTANEOUS 125319 001 2009-06-17   Start Trial UNIVERSITAT ZURICH (Zurich, CH) 2031-07-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Moodys
Boehringer Ingelheim
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.